Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma

A successful phase III trial for the combination of atezolizumab and bevacizumab (the IMbrave150 trial) in advanced hepatocellular carcinoma has recently been reported. This is groundbreaking because nivolumab and pembrolizumab, both programmed cell death-1 (PD-1) antibodies, have failed to show eff...

Descripción completa

Detalles Bibliográficos
Autor principal: Kudo, Masatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281246/
https://www.ncbi.nlm.nih.gov/pubmed/32349374
http://dx.doi.org/10.3390/cancers12051089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281246/
https://www.ncbi.nlm.nih.gov/pubmed/32349374
http://dx.doi.org/10.3390/cancers12051089

Ejemplares similares